vs
Side-by-side financial comparison of Akebia Therapeutics, Inc. (AKBA) and Nano Dimension Ltd. (NNDM). Click either name above to swap in a different company.
Nano Dimension Ltd. is the larger business by last-quarter revenue ($57.8M vs $57.6M, roughly 1.0× Akebia Therapeutics, Inc.). Akebia Therapeutics, Inc. produced more free cash flow last quarter ($31.1M vs $-21.1M).
Akebia Therapeutics is a biopharmaceutical company dedicated to developing and commercializing novel therapies for patients with kidney diseases, particularly anemia linked to chronic kidney disease. It operates across global markets, focusing on addressing unmet medical needs in the nephrology care segment.
Nano Dimension Ltd. is a leading provider of additively manufactured electronics solutions and 3D printing technologies. It designs high-precision 3D printers, related materials, and software for producing printed circuit boards, microelectronics components, and multi-layer electronic devices, serving aerospace, defense, medical, automotive, and industrial electronics segments across global markets.
AKBA vs NNDM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $57.6M | $57.8M |
| Net Profit | — | $-98.8M |
| Gross Margin | 78.2% | 43.1% |
| Operating Margin | -14.8% | -155.1% |
| Net Margin | — | -171.1% |
| Revenue YoY | 23.9% | — |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.05 | $-0.45 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.6M | — | ||
| Q3 25 | $58.8M | — | ||
| Q2 25 | $62.5M | — | ||
| Q1 25 | $57.3M | — | ||
| Q4 24 | $46.5M | $57.8M | ||
| Q3 24 | $37.4M | — | ||
| Q2 24 | $43.6M | $28.4M | ||
| Q1 24 | $32.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | $540.0K | — | ||
| Q2 25 | $247.0K | — | ||
| Q1 25 | $6.1M | — | ||
| Q4 24 | — | $-98.8M | ||
| Q3 24 | $-20.0M | — | ||
| Q2 24 | $-8.6M | $-79.2M | ||
| Q1 24 | $-18.0M | — |
| Q4 25 | 78.2% | — | ||
| Q3 25 | 84.0% | — | ||
| Q2 25 | 84.1% | — | ||
| Q1 25 | 86.7% | — | ||
| Q4 24 | 56.2% | 43.1% | ||
| Q3 24 | 62.2% | — | ||
| Q2 24 | 60.9% | 45.8% | ||
| Q1 24 | 64.4% | — |
| Q4 25 | -14.8% | — | ||
| Q3 25 | 7.6% | — | ||
| Q2 25 | 22.6% | — | ||
| Q1 25 | 23.6% | — | ||
| Q4 24 | -30.8% | -155.1% | ||
| Q3 24 | -33.4% | — | ||
| Q2 24 | -20.0% | — | ||
| Q1 24 | -45.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 10.7% | — | ||
| Q4 24 | — | -171.1% | ||
| Q3 24 | -53.5% | — | ||
| Q2 24 | -19.7% | -279.4% | ||
| Q1 24 | -55.2% | — |
| Q4 25 | $-0.05 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $0.03 | — | ||
| Q4 24 | $-0.10 | $-0.45 | ||
| Q3 24 | $-0.10 | — | ||
| Q2 24 | $-0.04 | $-0.35 | ||
| Q1 24 | $-0.09 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $184.8M | $317.2M |
| Total DebtLower is stronger | $48.3M | — |
| Stockholders' EquityBook value | $32.6M | $860.0M |
| Total Assets | $376.6M | $902.5M |
| Debt / EquityLower = less leverage | 1.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $184.8M | — | ||
| Q3 25 | $166.4M | — | ||
| Q2 25 | $137.3M | — | ||
| Q1 25 | $113.4M | — | ||
| Q4 24 | $51.9M | $317.2M | ||
| Q3 24 | $34.0M | — | ||
| Q2 24 | $39.5M | $231.8M | ||
| Q1 24 | $42.0M | — |
| Q4 25 | $48.3M | — | ||
| Q3 25 | $47.6M | — | ||
| Q2 25 | $47.1M | — | ||
| Q1 25 | $46.5M | — | ||
| Q4 24 | $38.7M | — | ||
| Q3 24 | $38.4M | — | ||
| Q2 24 | $38.0M | — | ||
| Q1 24 | $30.1M | — |
| Q4 25 | $32.6M | — | ||
| Q3 25 | $41.6M | — | ||
| Q2 25 | $29.2M | — | ||
| Q1 25 | $24.6M | — | ||
| Q4 24 | $-49.2M | $860.0M | ||
| Q3 24 | $-50.4M | — | ||
| Q2 24 | $-33.8M | $870.3M | ||
| Q1 24 | $-27.3M | — |
| Q4 25 | $376.6M | — | ||
| Q3 25 | $364.2M | — | ||
| Q2 25 | $345.6M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | $220.7M | $902.5M | ||
| Q3 24 | $207.1M | — | ||
| Q2 24 | $220.2M | $911.0M | ||
| Q1 24 | $225.5M | — |
| Q4 25 | 1.48× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.61× | — | ||
| Q1 25 | 1.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.1M | $-18.9M |
| Free Cash FlowOCF − Capex | $31.1M | $-21.1M |
| FCF MarginFCF / Revenue | 53.9% | -36.5% |
| Capex IntensityCapex / Revenue | 0.1% | 3.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $67.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.1M | — | ||
| Q3 25 | $28.1M | — | ||
| Q2 25 | $22.3M | — | ||
| Q1 25 | $-13.6M | — | ||
| Q4 24 | $-4.5M | $-18.9M | ||
| Q3 24 | $-6.7M | — | ||
| Q2 24 | $-10.1M | $-30.7M | ||
| Q1 24 | $-19.4M | — |
| Q4 25 | $31.1M | — | ||
| Q3 25 | $28.0M | — | ||
| Q2 25 | $22.2M | — | ||
| Q1 25 | $-13.6M | — | ||
| Q4 24 | $-4.5M | $-21.1M | ||
| Q3 24 | $-6.7M | — | ||
| Q2 24 | $-10.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | 53.9% | — | ||
| Q3 25 | 47.7% | — | ||
| Q2 25 | 35.6% | — | ||
| Q1 25 | -23.7% | — | ||
| Q4 24 | -9.6% | -36.5% | ||
| Q3 24 | -17.9% | — | ||
| Q2 24 | -23.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | 3.8% | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | 52.05× | — | ||
| Q2 25 | 90.47× | — | ||
| Q1 25 | -2.22× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AKBA
| Auryxia | $48.1M | 84% |
| Vafseo | $6.2M | 11% |
| License Collaboration And Other Revenue | $3.3M | 6% |
NNDM
Segment breakdown not available.
